Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study-Reference-Cited by-同舟云学术

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study

Published:2021-04-22 Issue:6 Volume:27 Page:1062-1070
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Li Jingxin,Hui Aimin^ORCID,Zhang Xiang,Yang Yumei,Tang Rong,Ye Huayue,Ji Ruiru,Lin Mei,Zhu Zhongkui,Türeci Özlem,Lagkadinou Eleni,Jia Siyue,Pan Hongxing,Peng Fuzhong,Ma Zhilong,Wu Zhenggang,Guo Xiling,Shi Yunfeng,Muik Alexander^ORCID,Şahin Uğur,Zhu Li^ORCID,Zhu Fengcai^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-021-01330-9.pdf

Reference29 articles.

1. Gudbjartsson, D. F. et al. Spread of SARS-CoV-2 in the Icelandic population. N. Engl. J. Med. 382, 2302–2315 (2020).

2. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).

3. World Health Organization. Weekly epidemiological update on COVID-19—6 April 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-april-2021 (2021).

4. Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2: preliminary report. N. Engl. J. Med. 383, 1920–1931 (2020).

5. World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (2021).

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection;Cell Reports;2024-07

2. Unlocking the potential of nanocarrier-mediated mRNA delivery across diverse biomedical frontiers: A comprehensive review;International Journal of Biological Macromolecules;2024-05

3. Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data;Human Vaccines & Immunotherapeutics;2024-02-26

4. Global research on RNA vaccines for COVID-19 from 2019 to 2023: a bibliometric analysis;Frontiers in Immunology;2024-02-15

5. Mathematical Optimization Strategy for Effectiveness Profile Estimation in Two-Dose Vaccines and Its Use in Designing Improved Vaccination Strategies Focused on Pandemic Containment;Vaccines;2024-01-12